Panakes Partners

Panakès Partners is a venture capital firm based in Milan, Italy, founded in 2015 by Fabrizio Landi, Alessio Beverina, and Diana Saraceni. The firm focuses on investing in early-stage startups and small to medium-sized enterprises within the life sciences sector across Europe and Israel. Panakès Partners seeks out ambitious companies and teams that are developing innovative technologies and products aimed at improving global health and quality of life. With a commitment to fostering revolutionary advancements in life sciences, the firm aims to support transformative solutions that address pressing health challenges.

Alessio Beverina

General Partner

Barbara Castellano

Partner

Fabrizio Landi

General Partner

Diana Saraceni

General Partner

Marco Sardina Ph.D

Scientific Partner

Rob Woodman

Partner

Alessio Piuma

Investment Manager

Past deals in Medical Devices

Neuromod Devices

Series B in 2025
Neuromod Devices Limited is a Dublin-based medical device company founded in 2010, focusing on the research and development of neuromodulation treatments for chronic tinnitus, a condition affecting approximately 10% of adults. The company has developed a patented bi-modal neuromodulation technology, exemplified by its product, the mutebutton. This device aims to promote positive therapeutic changes in the nervous system, offering a targeted approach to alleviate the suffering of patients living with chronic tinnitus. Neuromod is dedicated to providing innovative treatments that empower patients to manage their conditions while integrating seamlessly into their modern lifestyles.

Relief

Venture Round in 2025
Relief is a company that specializes in developing innovative medical devices aimed at treating urinary incontinence, particularly through the use of a unisex endo-urethral sphincter. This minimally invasive, magnetic device is designed for easy insertion and removal in an outpatient setting, making it accessible for patients. It effectively restores urinary control, even in those with severe forms of stress urinary incontinence. By offering a solution that is both invisible and user-friendly, Relief provides patients with a fast and effective treatment option that is also cost-efficient.

Endovascular Engineering

Series B in 2025
Endovascular Engineering is a preclinical stage company focused on developing innovative mechanical thrombectomy solutions aimed at addressing peripheral vascular conditions. The company specializes in creating and implementing advanced clot removal technologies specifically designed for venous thromboembolism, which includes treatment for significant health issues such as pulmonary embolism and deep vein thrombosis. By equipping healthcare professionals with effective medical tools, Endovascular Engineering aims to enhance the management of these critical conditions and improve patient outcomes.

TENSIVE

Series A in 2025
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Lymphatica Medtech

Series B in 2024
Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.

Alesi Surgical

Venture Round in 2024
Alesi Surgical Ltd. specializes in the development and commercialization of laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 and based in Cardiff, United Kingdom, the company emerged as a spin-out from the Welsh Institute for Minimal Access Therapy, benefiting from direct access to experienced surgeons and surgical trainers. Alesi Surgical's innovative products are designed to be portable and applicable in both laparoscopic and robot-assisted surgeries. Utilizing electrostatic precipitation technology, these tools effectively eliminate surgical smoke, ensuring a clear visual field during procedures. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia.

CorFlow

Series B in 2024
CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.

SamanTree Medical

Series B in 2024
SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room.

MMI

Series C in 2024
We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

CarThera

Series B in 2023
CarThera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices aimed at treating brain disorders. The company has created the SonoCloud®, an intracranial ultrasound implant that works in conjunction with a microbubble agent administered intravenously. This combination temporarily opens the blood-brain barrier, allowing for a significantly increased concentration of therapeutic molecules to penetrate the brain. By enhancing the delivery of treatments, CarThera's technology offers potential solutions for debilitating neurological conditions, providing healthcare professionals with new avenues for patient care.

EBAMed

Series A in 2023
EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Neuromod Devices

Series B in 2023
Neuromod Devices Limited is a Dublin-based medical device company founded in 2010, focusing on the research and development of neuromodulation treatments for chronic tinnitus, a condition affecting approximately 10% of adults. The company has developed a patented bi-modal neuromodulation technology, exemplified by its product, the mutebutton. This device aims to promote positive therapeutic changes in the nervous system, offering a targeted approach to alleviate the suffering of patients living with chronic tinnitus. Neuromod is dedicated to providing innovative treatments that empower patients to manage their conditions while integrating seamlessly into their modern lifestyles.

BetaGlue Technologies

Seed Round in 2022
BetaGlue Technologies SpA specializes in the development and manufacture of medical devices designed for loco-regional radiation therapy targeting unresectable solid tumors. The company's innovative product utilizes a proprietary beta-emitting bio-compatible matrix, facilitating the controlled administration of radionuclides directly into tumor masses. This technology not only aims to enhance treatment efficacy but also plays a crucial role in preventing complications that may arise from procedures such as lung and liver biopsies and other localized treatments. Headquartered in Milan, Italy, BetaGlue Technologies is focused on advancing therapeutic options in the field of oncology.

MMI

Series B in 2022
We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Alesi Surgical

Venture Round in 2021
Alesi Surgical Ltd. specializes in the development and commercialization of laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 and based in Cardiff, United Kingdom, the company emerged as a spin-out from the Welsh Institute for Minimal Access Therapy, benefiting from direct access to experienced surgeons and surgical trainers. Alesi Surgical's innovative products are designed to be portable and applicable in both laparoscopic and robot-assisted surgeries. Utilizing electrostatic precipitation technology, these tools effectively eliminate surgical smoke, ensuring a clear visual field during procedures. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia.

Salvia BioElectronics

Series A in 2020
Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

InnovHeart

Series B in 2020
InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company focuses on creating innovative implant technologies designed to treat patients with mitral valve disease. Its products aim to provide a safe, effective, and user-friendly solution for replacing incompetent mitral valves, allowing hospitals to address heart valve dysfunction more efficiently.

SamanTree Medical

Series A in 2019
SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room.

CarThera

Series B in 2018
CarThera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices aimed at treating brain disorders. The company has created the SonoCloud®, an intracranial ultrasound implant that works in conjunction with a microbubble agent administered intravenously. This combination temporarily opens the blood-brain barrier, allowing for a significantly increased concentration of therapeutic molecules to penetrate the brain. By enhancing the delivery of treatments, CarThera's technology offers potential solutions for debilitating neurological conditions, providing healthcare professionals with new avenues for patient care.

MMI

Series A in 2018
We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Alesi Surgical

Venture Round in 2017
Alesi Surgical Ltd. specializes in the development and commercialization of laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 and based in Cardiff, United Kingdom, the company emerged as a spin-out from the Welsh Institute for Minimal Access Therapy, benefiting from direct access to experienced surgeons and surgical trainers. Alesi Surgical's innovative products are designed to be portable and applicable in both laparoscopic and robot-assisted surgeries. Utilizing electrostatic precipitation technology, these tools effectively eliminate surgical smoke, ensuring a clear visual field during procedures. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia.

Seventeen

Series A in 2016
Seventeen is a medtech startup. The company intends to use the funds to finalize the technology and clinically validate it in order to obtain the CE mark.

Salvia BioElectronics

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.